Astellas acquires OSI Pharmaceuticals for $4 billion

Astellas Pharma of Japan is paying $4 billion in cash to acquire the US biotechnology company, OSI Pharmaceuticals Inc, giving it rights to the cancer drug, Tarceva (erlotinib). The purchase price is a sweetened $57.50 per share.